United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Achmea Investment Management B.V.

Achmea Investment Management B.V. raised its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 52.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,746 shares of the biotechnology company's stock after purchasing an additional 12,627 shares during the quarter. Achmea Investment Management B.V. owned about 0.08% of United Therapeutics worth $12,965,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Vestcor Inc lifted its holdings in shares of United Therapeutics by 40.7% during the 4th quarter. Vestcor Inc now owns 1,413 shares of the biotechnology company's stock valued at $499,000 after acquiring an additional 409 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of United Therapeutics by 32.6% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 14,532 shares of the biotechnology company's stock valued at $5,127,000 after acquiring an additional 3,573 shares in the last quarter. Avantax Advisory Services Inc. acquired a new position in shares of United Therapeutics during the 4th quarter valued at $209,000. Great Lakes Advisors LLC lifted its holdings in shares of United Therapeutics by 1.6% during the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock valued at $697,000 after acquiring an additional 31 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of United Therapeutics by 18.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 853 shares of the biotechnology company's stock valued at $301,000 after acquiring an additional 130 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on UTHR shares. HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, UBS Group lifted their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Louis W. Sullivan sold 26,209 shares of the business's stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares of the company's stock, valued at $1,885,134.22. The trade was a 83.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Nilda Mesa sold 255 shares of the business's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company's stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 116,464 shares of company stock valued at $42,396,244 in the last quarter. Insiders own 11.90% of the company's stock.

United Therapeutics Stock Up 0.6 %

Shares of UTHR traded up $1.85 during midday trading on Friday, hitting $307.24. The company had a trading volume of 494,807 shares, compared to its average volume of 445,927. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The company's 50 day moving average price is $349.77 and its 200 day moving average price is $358.48. The stock has a market cap of $13.80 billion, a price-to-earnings ratio of 13.49, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same quarter in the prior year, the firm earned $4.36 EPS. Equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.